secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024215
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q3 2022 net loss $29.1M; cash $393.3M; pipeline advances
---------------------------------------------------------------------------

- Net loss $29.1M ($0.33/share) vs $19.6M ($0.28) year ago; cash $393.3M sufficient into 2025.
- TNG908 phase 1/2 trial enrolling; CTA approved in France; initial safety and efficacy data expected H1 2023.
- Disclosed TNG260 as CoREST inhibitor for STK11-mutant cancers; IND filing on track for H1 2023.
- Declared TNG348 development candidate for BRCA1/2-mutant cancers; IND filing planned for 2023.
- Appointed Aaron Weitzman as CMO; R&D expenses $28.7M, G&A $8.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017022024215/0000950170-22-024215-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017022024215/tngx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024215

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer